Many Important November Developments for Precision Therapeutics

Pittsburgh, PA ( Pressreleasecollection ) December 23, 2009 – Precision Therapeutics was recognized by Inc. Magazine as the 64th fastest growing privately owned healthcare company in the US and placed within the top 83 percentile of all private U.S. companies with a three year growth rate of 351percent. The Inc. 500/5000 is an annual ranking that recognizes the significant accomplishments of the fastest-growing privately held entrepreneurial companies in America, whose unsurpassed innovation, creativity and performance have redefined their industry.

“We are very excited and honored to be ranked 64 of 100 in the health category of the Inc. 500,” said McDonald. “Our success and subsequent ranking on this list reflects the passion of Precision Therapeutics employees and the commitment Pittsburgh has made to supporting local businesses in the region.”

Precision Therapeutics and the other Inc. 5000 companies are responsible for creating more than 1 million jobs since their founding; making the list perhaps the best example of the impact that private, fast-growing companies can have on the economy.

For a complete copy of the press release, please visit our ChemoFx® website at: http://www.chemofx.com/chemotherapy-news/chemotherapy-news.html

New Website Feature on www.ChemoFx.com

As part of Precision Therapeutics’ continuing efforts to make ChemoFx® and personalized chemotherapy available to more patients in need, we are adding a “Find a Doctor” function on our website that will allow patients to search for physicians in their area who use the ChemoFx® Drug Response Marker. If you would like to be included in our “Find a Doctor” function and have not received a letter or e-mail, please contact Becky Yacht at: byacht@ptilabs.com, or speak with your Clinical Oncology Specialist (COS) for more information.

ChemoFx Reference Guide

For physicians wanting more information about ChemoFx®, we will soon offer a CD kit that includes our full list of publications, a sample final report, patient billing information and much more. If you are interested in receiving this kit, contact your local COS and one will be sent to you hot off the CD burner!

Precision Therapeutics to Open Third Facility

Precision has committed to leasing additional laboratory space in Pittsburgh’s Lawrenceville neighborhood. Approximately 80 employees will work from this new location, which is expected to be occupied by summer 2010.

Precision Launches into Lung

Lung cancer panels for both the primary and recurrent setting will be added to our list of standard drug panels this November. These lists of available agents will include Pemetrexed, making us the first and only drug response marker or assay to offer sensitivity and resistance testing for the popular lung cancer drug. Our standard panel for renal cancer will also be updated with the addition of sunitinib. These are important steps as we continue exploring and verifying the effectiveness of ChemoFx® as a diagnostic tool for various tumor types.

New Publication in Anticancer Research: Assessment of Erlotinib in Chemoresponse Assay*

A new article on the ability of ChemoFx® to successfully test for patient response to erlotinib was recently published in Anticancer Research. In this study, three different non-small-cell lung cancer cell lines and 34 primary human lung tumor specimens were tested for chemoresponse to the drug. The relative responsiveness of the specimens was found to be consistent with previously published patterns of response, with 8.8% of cultures scored as “responsive” by the DRM, compared to the 8.9% objective clinical response rate reported in published literature. This serves as validation of our ability to successfully test for patient response to erlotinib with the ChemoFx® Drug Response Marker.

*Shara D Rice, Bush. J.A., Brower, S.L. Assessment of Erlotinib in Chemoresponse Assay. Anticancer Research (2009) 29:1993-1198

What we do

Precision Therapeutics is a CLIA-certified diagnostics services company dedicated to providing physicians and patients with actionable clinical information to personalize cancer treatments. Precision’s ChemoFx®, a proprietary live tumor cell-based platform, measures an individual patient’s tumor sensitivity and resistance to a range of therapeutic alternatives under consideration by a physician. This may help guide physicians when evaluating each patient’s cancer treatment options.

###